$70.42
-0.58[-0.82%]
Last update: 2:47PM Get Real Time Here
Ligand Pharmaceuticals
(NASDAQ:LGND)Latest News for Ligand Pharmaceuticals Stock (NASDAQ:LGND)
Ligand Pharmaceuticals Stock (NASDAQ: LGND)
Categories: All
Friday, April 12, 2024
Monday, April 08, 2024
Wednesday, April 03, 2024
Thursday, March 28, 2024
Thursday, February 29, 2024
Tuesday, February 27, 2024
- Why Is Ligand Pharmaceuticals Stock Trading Higher Today?Vandana Singh - Feb 27, 2024, 2:08PM
- Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionAvi Kapoor - Feb 27, 2024, 1:18PM
- Ligand Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results and issued guidance.Benzinga Newsdesk - Feb 27, 2024, 12:12PM
- Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On TuesdayAvi Kapoor - Feb 27, 2024, 10:27AM
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - Feb 27, 2024, 8:06AM
- Ligand Reaffirms FY24 EPS Guidance Of $4.25-$4.75 Vs $4.27 Est.; Revenue $130M-$142M Vs $138.5M Est.Benzinga Newsdesk - Feb 27, 2024, 7:12AM
- Ligand Pharmaceuticals Q4 EPS $1.38 Beats $0.66 Estimate, Sales $28.10M Beat $25.72M EstimateBenzinga Newsdesk - Feb 27, 2024, 7:06AM
- Earnings Scheduled For February 27, 2024Benzinga Insights - Feb 27, 2024, 5:01AM
Monday, February 26, 2024
Thursday, February 22, 2024
Thursday, January 11, 2024
Wednesday, December 13, 2023
Tuesday, December 12, 2023
- Ligand Provides A 5-Year Outlook; Adjusted Diluted EPS Outlook For 2028 Is In The Range Of $10.00-$10.50; Total Core Revenue Could Reach ~$290M By 2028Benzinga Newsdesk - Dec 12, 2023, 12:07PM
- Ligand Holds Investor And Analyst Day; Provides Update On Portfolio Progress And Recent Transactions; Introduces 2024 Guidance; Sees FY24 EPS $4.25-$4.75 Vs $4.17 Est.; Revenue $130M-$142M Vs $138.6M Est.Benzinga Newsdesk - Dec 12, 2023, 12:06PM
Tuesday, November 28, 2023
Wednesday, November 08, 2023
- Ligand Sees Q3 2023 Revenue $126M-$129M Vs $126.5M Estimate, $124M-$126M PriorBenzinga Newsdesk - Nov 8, 2023, 5:44PM
- Ligand Pharmaceuticals Q3 Adj EPS $1.02 Beats $0.61 Estimate, Sales $32.87M Beat $27.19M EstimateBenzinga Newsdesk - Nov 8, 2023, 4:18PM
- Ligand Pharmaceuticals: Q3 Earnings InsightsBenzinga Insights - Nov 8, 2023, 4:10PM
- Earnings Scheduled For November 8, 2023Benzinga Insights - Nov 8, 2023, 4:21AM
Wednesday, October 18, 2023
Wednesday, September 27, 2023
Tuesday, September 26, 2023
Friday, September 22, 2023
Tuesday, September 19, 2023
- Ligand Pharma Updates Annual Guidance As It Spins Out Pelican SubsidiaryVandana Singh - Sep 19, 2023, 1:15PM
- Where Ligand Pharmaceuticals Stands With AnalystsBenzinga Insights - Sep 19, 2023, 1:00PM
- HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $144 Price TargetBenzinga Newsdesk - Sep 19, 2023, 12:01PM
Monday, September 18, 2023
- Ligand Pharmaceuticals Revises FY23 Revenue Outlook From $124M-$128M To $124M-$126M; Est. $127.05MBenzinga Newsdesk - Sep 18, 2023, 5:24PM
- Ligand Pharmaceuticals Boosts FY23 Adjusted EPS Outlook From $4.85-$5.00 To $5.10-$5.25; Est $4.98Benzinga Newsdesk - Sep 18, 2023, 5:22PM
- Ligand Spins Out And Merges Pelican Subsidiary With Primordial Genetics To Create Primrose BioBenzinga Newsdesk - Sep 18, 2023, 5:18PM
Tuesday, September 05, 2023
Wednesday, August 23, 2023
Wednesday, August 09, 2023
Tuesday, August 08, 2023
Tuesday, July 25, 2023
Monday, July 17, 2023
- Why Are Novan Shares Nosediving Today?Vandana Singh - Jul 17, 2023, 10:25AM
- Novan Enters Into Agreement To Sell Substantially All Of Its Assets, Including Berdazimer Gel, 10.3%, And Files For Chapter 11 Protection; Announces Commitment From Ligand To Fund $15M In Debtor-In-Posession FinancingBenzinga Newsdesk - Jul 17, 2023, 8:48AM